Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844–53.

Article  PubMed  PubMed Central  Google Scholar 

Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495–6.

Article  CAS  PubMed  Google Scholar 

Harrison RK. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov. 2016;15(12):817–8.

Article  CAS  PubMed  Google Scholar 

Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol. 2021;18(6):435–53.

Article  PubMed  Google Scholar 

Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856–60.

Article  CAS  PubMed  Google Scholar 

Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581–94.

Article  CAS  PubMed  Google Scholar 

Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021;22(10):658–71.

Article  CAS  PubMed  Google Scholar 

Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.

Article  CAS  PubMed  Google Scholar 

Lopalco L. CCR5: from natural resistance to a new anti-HIV strategy. Viruses. 2010;2(2):574–600.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, et al. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med. 2021;27(4):668–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48(3):245–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481–7.

Article  CAS  PubMed  Google Scholar 

Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome analyzes in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022;54(5):593–602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712–21.

Article  CAS  PubMed  Google Scholar 

Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:383.

Article  Google Scholar 

Lopera-Maya EA, Kurilshikov A, van der Graaf A, Hu S, Andreu-Sánchez S, Chen L, et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch microbiome project. Nat Genet. 2022;54(2):143–51.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.

Article  PubMed  PubMed Central  Google Scholar 

DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tao S, Rojo de la Vega M, Chapman E, Ooi A, Zhang DD. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog. 2018;57(2):182–92.

Article  CAS  PubMed  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

Article  CAS  PubMed  Google Scholar 

Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21–43.

Article  CAS  PubMed  Google Scholar 

Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.

Article  PubMed  Google Scholar 

Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergstrom EN, Luebeck J, Petljak M, Khandekar A, Barnes M, Zhang T, et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature. 2022;602(7897):510–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petljak M, Dananberg A, Chu K, Bergstrom EN, Striepen J, von Morgen P, et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature. 2022;607(7920):799–807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. 2023;620(7973):393–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2011;15(7):1957–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J, Zhou GW, Wang N, Wang YJ. GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;124(2):425–31.

Article  CAS  PubMed  Google Scholar 

Men T, Zhang X, Yang J, Shen B, Li X, Chen D, et al. The rs1050450 C > T polymorphism of GPX1 is associated with the risk of bladder but not prostate cancer: evidence from a meta-analysis. Tumor Biol. 2014;35(1):269–75.

Article  CAS  Google Scholar 

Erdem O, Eken A, Akay C, Arsova-Sarafinovska Z, Matevska N, Suturkova L, et al. Association of GPX1 polymorphism, GPX activity and prostate cancer risk. Hum Exp Toxicol. 2012;31(1):24–31.

Article  CAS  PubMed  Google Scholar 

Raaschou-Nielsen O, Sørensen M, Hansen RD, Frederiksen K, Tjønneland A, Overvad K, et al. GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett. 2007;247(2):293–300.

Article  CAS  PubMed  Google Scholar 

Hansen R, Saebø M, Skjelbred CF, Nexø BA, Hagen PC, Bock G, et al. GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005;229(1):85–91.

Article  CAS  PubMed  Google Scholar 

Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 2013;73(13):4158–68.